BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Berobenatide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Berobenatide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07508241-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270127
DTEND;VALUE=DATE:20270128
SUMMARY:Berobenatide: Phase 1 readout est. (NCT07508241)
DESCRIPTION:Berobenatide\, phase 1\, Obesity.\nStudy: A Study to Learn Abou
 t the Effect of Study Medicine Called PF-08653944 on How Quickly the Stoma
 ch Empties Its Content in Healthy Adults With Overweight or Obesity\nEstim
 ated primary completion: 27 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07508241
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845513-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270221
DTEND;VALUE=DATE:20270222
SUMMARY:Berobenatide: Phase 1 readout est. (NCT07845513)
DESCRIPTION:Berobenatide\, phase 1\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adult
 s With Overweight or Obesity\nEstimated primary completion: 21 February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07845513
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876531-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Berobenatide: Phase 1 readout est. (NCT07876531)
DESCRIPTION:Berobenatide\, phase 1\, Obesity.\nStudy: A Study to Learn How 
 Different Forms of the Study Medicine Called Berobenatide is Taken up Into
  the Blood in Adults With Overweight or Obesity\nEstimated primary complet
 ion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 robenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07876531
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519135-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Berobenatide: Phase 1 readout est. (NCT07519135)
DESCRIPTION:Berobenatide\, phase 1.\nStudy: A Study to Learn About the Medi
 cine Called PF-08653944 in People With and Without Reduced Liver Function\
 nEstimated primary completion: 9 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07519135
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575932-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:Berobenatide: Phase 2 readout est. (NCT07575932)
DESCRIPTION:Berobenatide\, phase 2\, Obesity.\nStudy: A Study of PF-0865394
 5 and PF-08653944 in Adults With Overweight or Obesity\nEstimated primary 
 completion: 4 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/berobenatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07575932
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311850-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07311850)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f MET097 Once-Weekly in People With Overweight or Obesity\nEstimated prima
 ry completion: 21 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07311850
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400653-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07400653)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine (PF-08653944) in People With Obesity or Overweight an
 d Type 2 Diabetes (T2D)\nEstimated primary completion: 12 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07400653
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845500-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07845500)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) 
 to Help Keep Weight Off in People With Overweight or Obesity\nEstimated pr
 imary completion: 16 February 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07845500
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792954-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280314
DTEND;VALUE=DATE:20280315
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07792954)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Plac
 ebo in Chinese Adults With Overweight or Obesity\nEstimated primary comple
 tion: 14 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 berobenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07792954
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823608-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07823608)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Monthly Dosing Study Medicine Called Berobenatide in Adults With Bre
 athing Problems During Sleep and Overweight or Obesity Who Use a Breathing
  Machine (PAP) (VESPER-OSA 1)\nEstimated primary completion: 30 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07823608
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595549-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280504
DTEND;VALUE=DATE:20280505
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07595549)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called Berobenatide (PF-08653944) in People With Over
 weight or Obesity\nEstimated primary completion: 4 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07595549
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881757-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07881757)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Monthly Dosing Study Medicine Called Berobenatide in Adults With Bre
 athing Problems During Sleep and Overweight or Obesity Who Do Not Use a Br
 eathing Machine (PAP) (VESPER-OSA 2)\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07881
 757
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874633-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07874633)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Pla
 cebo in Chinese Adults With Overweight or Obesity\nEstimated primary compl
 etion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 erobenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07874633
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915609-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280821
DTEND;VALUE=DATE:20280822
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07915609)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Ov
 erweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)\nEstimat
 ed primary completion: 21 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07915609
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919678-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280822
DTEND;VALUE=DATE:20280823
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07919678)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Study Medicine Called Berobenatide in Adults With Knee Pain and Overweig
 ht or Obesity (VESPER-OA 1)\nEstimated primary completion: 22 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07919678
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932925-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07932925)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Safety and Effectiveness of Berobenatide in Women With Urine Leakage
  and With Obesity or Overweight (VESPER-SUI)\nEstimated primary completion
 : 13 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 robenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07932925
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794774-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290221
DTEND;VALUE=DATE:20290222
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07794774)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Safety and Effects of Once-monthly Treatment With Berobenatide in Adults
  With Obesity Disease in Japan (VESPER-JM)\nEstimated primary completion: 
 21 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ber
 obenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07794774
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794761-179@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290314
DTEND;VALUE=DATE:20290315
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07794761)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Safety and Effects of Once-weekly Treatment With Berobenatide in Adults 
 With Obesity Disease in Japan (VESPER-JW)\nEstimated primary completion: 1
 4 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beroben
 atide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07794761
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
